AVA-ADR-001

AVA-ADR-001 is a first-in-class, potent, and selective small molecule inhibitor targeting the Zα domain of the ADAR1 p150 isoform. Developed by Avammune Therapeutics, this compound directly binds to the Zα domain of ADAR1 p150, resulting in selective inhibition. Mechanistically, AVA-ADR-001 induces a strong interferon (IFN) response in an MDA5-dependent manner and upregulates several interferon-stimulated genes such as IFIH1, IFN-beta, and CXCL10. Preclinical studies have demonstrated significant anti-tumor efficacy in syngeneic melanoma mouse models both as monotherapy (45% tumor growth inhibition) and synergistically when combined with anti-PD1 therapy. The drug’s mechanism involves activation of PKR leading to protein translation inhibition and cell proliferation arrest. Its primary development focus is for cancer immunotherapy—specifically neoplasms including melanoma[2][4][5][6].